JP2024508709A - 抗ｃｄ１２３結合分子及びその使用法 - Google Patents

抗ｃｄ１２３結合分子及びその使用法 Download PDF

Info

Publication number
JP2024508709A
JP2024508709A JP2023548578A JP2023548578A JP2024508709A JP 2024508709 A JP2024508709 A JP 2024508709A JP 2023548578 A JP2023548578 A JP 2023548578A JP 2023548578 A JP2023548578 A JP 2023548578A JP 2024508709 A JP2024508709 A JP 2024508709A
Authority
JP
Japan
Prior art keywords
seq
antibody
fragment
binding
igm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508709A5 (https=
Inventor
ポール アール． ヒントン
マナル アマウリー
Original Assignee
アイジーエム バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイジーエム バイオサイエンシズ インコーポレイテッド filed Critical アイジーエム バイオサイエンシズ インコーポレイテッド
Publication of JP2024508709A publication Critical patent/JP2024508709A/ja
Publication of JP2024508709A5 publication Critical patent/JP2024508709A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023548578A 2021-02-17 2022-02-17 抗ｃｄ１２３結合分子及びその使用法 Pending JP2024508709A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163150488P 2021-02-17 2021-02-17
US63/150,488 2021-02-17
US202163249455P 2021-09-28 2021-09-28
US63/249,455 2021-09-28
PCT/US2022/016683 WO2022178047A1 (en) 2021-02-17 2022-02-17 Anti-cd123 binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2024508709A true JP2024508709A (ja) 2024-02-28
JP2024508709A5 JP2024508709A5 (https=) 2025-02-21

Family

ID=82931699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548578A Pending JP2024508709A (ja) 2021-02-17 2022-02-17 抗ｃｄ１２３結合分子及びその使用法

Country Status (9)

Country Link
US (1) US20240076392A1 (https=)
EP (1) EP4294829A4 (https=)
JP (1) JP2024508709A (https=)
KR (1) KR20230146022A (https=)
AU (1) AU2022221633A1 (https=)
CA (1) CA3205834A1 (https=)
IL (1) IL304485A (https=)
MX (1) MX2023009615A (https=)
WO (1) WO2022178047A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130635A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
JP2019024499A (ja) * 2013-03-05 2019-02-21 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫療法のためのエンゲージャー細胞
WO2019169314A1 (en) * 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
JP2020512820A (ja) * 2017-04-07 2020-04-30 アイジーエム バイオサイエンシズ インコーポレイテッド 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域
JP2020522498A (ja) * 2017-06-01 2020-07-30 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１２３ ｃｄ３に結合する二重特異性抗体
JP7585305B2 (ja) * 2019-08-17 2024-11-18 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3957738A1 (en) * 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN109952112B (zh) * 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
BR112019010061A2 (pt) * 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
EP3853254A1 (en) * 2018-09-20 2021-07-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
JP2022532868A (ja) * 2019-05-04 2022-07-20 インヒブルクス インコーポレイテッド Ｃｄ１２３結合性ポリペプチド及びその使用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130635A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
JP2019024499A (ja) * 2013-03-05 2019-02-21 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫療法のためのエンゲージャー細胞
JP2020512820A (ja) * 2017-04-07 2020-04-30 アイジーエム バイオサイエンシズ インコーポレイテッド 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域
JP2020522498A (ja) * 2017-06-01 2020-07-30 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１２３ ｃｄ３に結合する二重特異性抗体
WO2019169314A1 (en) * 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
JP7585305B2 (ja) * 2019-08-17 2024-11-18 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CORNELIA HUTMACHER ET AL.: "Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.", LEUKEMIA RESEARCH, vol. 84, JPN7026000716, 2019, pages 106178, ISSN: 0005799543 *
RAMESH BALIGA ET AL.: "High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing", BLOOD, vol. 134, JPN7026000718, 2019, pages 1574, ISSN: 0005799545 *
SEUNG Y. CHU ET AL.: "Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-", BLOOD, vol. 124, JPN7026000717, 2014, pages 2316, ISSN: 0005799544 *
XING DU ET AL.: "New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.", JOURNAL OF IMMUNOTHERAPY, vol. 30, JPN7026000719, 2007, pages 607 - 613, ISSN: 0005799546 *
YAGHOUB SAFDARI ET AL.: "Antibody humanization methods - a review and update.", BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, vol. 29, JPN7026000720, 2013, pages 175 - 186, ISSN: 0005799547 *

Also Published As

Publication number Publication date
EP4294829A1 (en) 2023-12-27
KR20230146022A (ko) 2023-10-18
AU2022221633A1 (en) 2023-08-10
IL304485A (en) 2023-09-01
CA3205834A1 (en) 2022-08-25
US20240076392A1 (en) 2024-03-07
EP4294829A4 (en) 2025-03-19
WO2022178047A1 (en) 2022-08-25
AU2022221633A9 (en) 2024-07-11
MX2023009615A (es) 2023-08-24

Similar Documents

Publication Publication Date Title
CN114341179B (zh) 多聚体双特异性抗cd123结合分子及其用途
JP2024177479A (ja) 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
JP2024508709A (ja) 抗ｃｄ１２３結合分子及びその使用法
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
AU2020351205A1 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
KR20220050166A (ko) Igm 글리코변이체
US20250051473A1 (en) Anti-cd38 binding molecules and uses thereof
WO2023064900A1 (en) Methods of use of multimeric anti-pd-l1 binding molecules
CN116964081A (zh) 抗cd123结合分子及其用途
CN118679185A (zh) 抗cd38结合分子及其用途
BR112022002897B1 (pt) Anticorpo multimérico e biespecífico e uso do mesmo para tratar leucemia mieloide aguda
CA3091144A1 (en) Igm fc and j-chain mutations that affect igm serum half-life

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406